Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
Hostname: page-component-ffbbcc459-7mr6j Total loading time: 0.446 Render date: 2022-03-13T06:04:42.746Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }
  • English
British Journal of Nutrition British Journal of Nutrition

Article contents

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract

Published online by Cambridge University Press:  16 September 2011

Takashi Hashimoto ,
Yoshiaki Ozaki ,
Masashi Mizuno ,
Masaru Yoshida ,
Yosuke Nishitani ,
Takeshi Azuma ,
Akitoshi Komoto ,
Takashi Maoka ,
Yuka Tanino  and
Kazuki Kanazawa
Takashi Hashimoto*
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Yoshiaki Ozaki
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Masashi Mizuno
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Masaru Yoshida
Affiliation:
Department of Internal Medicine, Kobe University, Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe, 650-0017Hyogo, Japan
Yosuke Nishitani
Affiliation:
Organization of Advanced Science and Technology, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Takeshi Azuma
Affiliation:
Department of Internal Medicine, Kobe University, Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe, 650-0017Hyogo, Japan
Akitoshi Komoto
Affiliation:
Ogurayayamamoto Company, 2-124 Wakabayashi, Yao, Osaka581-0038, Japan
Takashi Maoka
Affiliation:
Research Institute for Production Development, 15 Shimogamo-morimoto, Sakyo, Kyoto606-0805, Japan
Yuka Tanino
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Kazuki Kanazawa
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
*
*Corresponding author: Dr T. Hashimoto, fax +81 78 803 5899, email takashi@kobe-u.ac.jp
Rights & Permissions[Opens in a new window]

Abstract

HTML view is not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Dietary fucoxanthin has been reported to exert several physiological functions, and fucoxanthinol is considered to be the primary active metabolite of fucoxanthin. However, there is no information about the pharmacokinetics of fucoxanthinol in human subjects. In the present study, eighteen human volunteers were orally administered kombu extract containing 31 mg fucoxanthin, and their peripheral blood was collected 5 min before and 0·5, 1, 2, 4, 8 and 24 h after the treatment. Plasma fucoxanthinol concentrations were measured by HPLC, and the pharmacokinetics of fucoxanthinol were as follows: maximum concentration, 44·2 nmol/l; time at maximum concentration, 4 h; terminal half-time, 7·0 h; area under the curve (AUC) for 1–24 h, 578·7 nmol/l × h; AUC(∞), 663·7 nmol/l × h. In addition to fucoxanthinol, we also attempted to detect amarouciaxanthin A, a hepatic metabolite of fucoxanthinol, using HPLC, but it was not present in the volunteers' plasma. On the other hand, a peak that was suspected to represent the cis-isomer of fucoxanthinol was found in the HPLC chromatogram. By comparing the present results with those of a previous study using mice, we found that the bioavailability and metabolism of fucoxanthinol differ between human subjects and mice.

Keywords

FucoxanthinolFucoxanthinHuman subjectsPlasmaKombu (Laminaria japonica)
Type
Short Communication
Information
British Journal of Nutrition , Volume 107 , Issue 11 , 14 June 2012 , pp. 1566 - 1569
Copyright
Copyright © The Authors 2011

References

1Haugan, JA, Aakermann, T & Liaaen-Jensen, S (1992) Isolation of fucoxanthin and peridinin. Methods Enzymol 213, 231–245.CrossRefGoogle Scholar
2Okuizumi, J, Takahashi, T, Yamane, T, et al. (1993) Inhibitory effects of fucoxanthin, a natural carotenoid, on N-ethyl-N(-nitro-N-nitrosoguanidine-induced mouse duodenal carcinogenesis. Cancer Lett 68, 159–168.CrossRefGoogle Scholar
3Das, SK, Hashimoto, T, Baba, M, et al. (2006) Japanese kelp (kombu) extract suppressed the formation of aberrant crypt foci in azoxymethane challenged mouse colon. J Clin Biochem Nutr 38, 119–125.CrossRefGoogle Scholar
4Kotake-Nara, E, Kushiro, M, Zhang, H, et al. (2001) Carotenoids affect proliferation of human prostate cancer cells. J Nutr 131, 3303–3306.CrossRefGoogle ScholarPubMed
5Hosokawa, M, Kudo, M, Maeda, H, et al. (2004) Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARγ ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 1675, 113–119.CrossRefGoogle ScholarPubMed
6Das, SK, Hashimoto, T, Shimizu, K, et al. (2005) Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta 1726, 328–335.CrossRefGoogle ScholarPubMed
7Azuma, Y, Hashimoto, T, Nomura, H, et al. (2008) Fucoxanthin induced apoptosis in human hepatocarcinoma HepG2 cells. J Clin Biochem Nutr 43, 273–276.Google Scholar
8Maeda, H, Hosokawa, M, Sashima, T, et al. (2006) Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int J Mol Med 18, 147–152.Google ScholarPubMed
9Maeda, H, Hosokawa, M, Sashima, T, et al. (2005) Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 332, 392–397.CrossRefGoogle ScholarPubMed
10Sugawara, T, Baskaran, V, Tsuzuki, W, et al. (2002) Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr 132, 946–951.CrossRefGoogle ScholarPubMed
11Asai, A, Sugawara, T, Ono, H, et al. (2004) Biotransformation of fucoxanthinol into amaroucixanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos 32, 205–211.CrossRefGoogle ScholarPubMed
12Hashimoto, T, Ozaki, Y, Taminato, M, et al. (2009) The distribution and accumulation of fucoxanthin and its metabolites after oral-administration in mice. Br J Nutr 102, 242–248.CrossRefGoogle ScholarPubMed
13Ozaki, Y, Katsumata, S, Uehara, M, et al. (2008) Accumulation of fucoxanthin and its metabolites in mice after ad libitum administration of kombu extract-containing diet for one month. J Clin Biochem Nutr 43, (Suppl. 1), 269–272.Google Scholar
14Asai, A, Yonekura, L & Nagao, A (2008) Low bioavailability of dietary epoxyxanthophylls in humans. Br J Nutr 100, 273–277.CrossRefGoogle ScholarPubMed
15Tabata, K, Yamaoka, K, Kaibara, A, et al. (1999) Moment analysis program available on Microsoft Excel. Xenobio Metabol Dispos 14, 286–293.Google Scholar
16Novotny, JA, Kurilich, AC, Britz, SJ, et al. (2005) Plasma appearance of labeled β-carotene, lutein, and retinol in humans after consumption of isotopically labeled kale. J Lipid Res 46, 1896–1903.CrossRefGoogle ScholarPubMed
17Mercke Odeberg, J, Lignell, Å, Pettersson, A, et al. (2003) Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci 19, 299–304.CrossRefGoogle ScholarPubMed
18Mordenti, J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharma Sci 75, 1028–1040.CrossRefGoogle ScholarPubMed
19Kistler, A, Liechti, H, Pichard, L, et al. (2002) Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch Toxicol 75, 665–675.CrossRefGoogle ScholarPubMed
20Toyokawa, H (1978) Nutritional status in Japan from the viewpoint of numerical ecology. Soc Sci Med 12, 517–524.Google ScholarPubMed
21Abidov, M, Ramazanov, Z, Seifulla, R, et al. (2010) The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab 12, 72–81.CrossRefGoogle ScholarPubMed
You have Access
57
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *